Sunday, 21 February 2021

Vaccine shows potential against deadly leptospirosis bacteria


Researchers have reported success with a new protective vaccine that shows considerable potential against deadly leptospirosis bacteria. The disease can cause considerable lung damage.


New research of interest has been published in the journal eLife ("A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus"). 
 
This is based on a study that discusses how a single-dose universal vaccine could protect against the many forms of leptospirosis bacteria, which cause life-threatening conditions such as Weil’s disease and lung haemorrhage.  
 
 
 
Leptospira bacteria refers to genus of spirochaete bacteria, including a small number of pathogenic and saprophytic species. The bacteria are flexulous, in terms of being able to bend and wriggle as well as motile, in terms of being able to propel themselves about. It is of medical concern that the disease caused by the bacterium is manifest as a wide range of symptoms, some of which may be mistaken for other diseases. 
 
The time between exposure to the bacteria which causes leptospirosis and when symptoms first become apparent is 7 to 21 days.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

No comments:

Post a comment

Pharmaceutical Microbiology Resources

Special offers